Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Chief Scientific Officer | October 07, 2021 | October 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date October 07, 2021 · Filed October 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-10-07 | Direct | 28,252 |
Reported balance
After 2021-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-07 · Grant · Acquired 28,252 · Balance 28,252 F1: These stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2021 Filed Oct 12, 2021 19:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 28,252 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034420 · form4.xml · derivative · entry 1 Herbst Ronald · CIK 0001886107 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,252 Underlying: Common Stock · 28,252 shares Expires 2031-10-07 F1 · derivative.exercise_date: These stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.